PortfoliosLab logoPortfoliosLab logo
LAZR vs. BOLT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

LAZR vs. BOLT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Luminar Technologies, Inc. (LAZR) and Bolt Biotherapeutics, Inc. (BOLT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


LAZR

1D
0.00%
1M
0.00%
YTD
0.00%
6M
-78.56%
1Y
-94.52%
3Y*
-87.69%
5Y*
-77.92%
10Y*

BOLT

1D
-9.39%
1M
-8.50%
YTD
-15.33%
6M
-12.14%
1Y
-23.72%
3Y*
-48.55%
5Y*
-57.48%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

LAZR vs. BOLT - Yearly Performance Comparison


2026 (YTD)20252024202320222021
LAZR
Luminar Technologies, Inc.
0.00%-96.50%-89.36%-31.92%-70.73%-49.30%
BOLT
Bolt Biotherapeutics, Inc.
-15.33%-48.91%-52.22%-13.85%-73.47%-84.76%

Correlation

The correlation between LAZR and BOLT is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.15

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.18

Correlation (All Time)
Calculated using the full available price history since Feb 8, 2021

0.19

Fundamentals

EPS

LAZR:

-$3.95

BOLT:

-$5.26

PS Ratio

LAZR:

0.15

BOLT:

4.01

Total Revenue (TTM)

LAZR:

$75.75M

BOLT:

$6.50M

Gross Profit (TTM)

LAZR:

-$16.13M

BOLT:

$4.98M

EBITDA (TTM)

LAZR:

-$161.26M

BOLT:

-$28.67M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

LAZR vs. BOLT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LAZR
LAZR Risk / Return Rank: 1010
Overall Rank
LAZR Sharpe Ratio Rank: 2323
Sharpe Ratio Rank
LAZR Sortino Ratio Rank: 1212
Sortino Ratio Rank
LAZR Omega Ratio Rank: 88
Omega Ratio Rank
LAZR Calmar Ratio Rank: 00
Calmar Ratio Rank
LAZR Martin Ratio Rank: 88
Martin Ratio Rank

BOLT
BOLT Risk / Return Rank: 2626
Overall Rank
BOLT Sharpe Ratio Rank: 2727
Sharpe Ratio Rank
BOLT Sortino Ratio Rank: 3030
Sortino Ratio Rank
BOLT Omega Ratio Rank: 3030
Omega Ratio Rank
BOLT Calmar Ratio Rank: 2222
Calmar Ratio Rank
BOLT Martin Ratio Rank: 2121
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LAZR vs. BOLT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Luminar Technologies, Inc. (LAZR) and Bolt Biotherapeutics, Inc. (BOLT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


LAZRBOLTDifference
Sharpe ratioReturn per unit of total volatility

-0.09

Sortino ratioReturn per unit of downside risk

-0.87

Omega ratioGain probability vs. loss probability

0.84

1.00

-0.16

Calmar ratioReturn relative to maximum drawdown

-1.02

-0.53

-0.49

Martin ratioReturn relative to average drawdown

-1.39

-0.98

-0.41

LAZR vs. BOLT - Sharpe Ratio Comparison

The current LAZR Sharpe Ratio is -0.41, which is comparable to the BOLT Sharpe Ratio of -0.33. The chart below compares the historical Sharpe Ratios of LAZR and BOLT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


LAZRBOLTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.41

-0.33

-0.09

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.60

-0.78

+0.18

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.53

-0.80

+0.28

Drawdowns

LAZR vs. BOLT - Drawdown Comparison

The maximum LAZR drawdown since its inception was -99.97%, roughly equal to the maximum BOLT drawdown of -99.51%. Use the drawdown chart below to compare losses from any high point for LAZR and BOLT.


Loading charts...

Drawdown Indicators


LAZRBOLTDifference

Max Drawdown

Largest peak-to-trough decline

-99.97%

-99.51%

-0.46%

Max Drawdown (1Y)

Largest decline over 1 year

-95.02%

-44.85%

-50.17%

Max Drawdown (3Y)

Largest decline over 3 years

-99.85%

-88.36%

-11.49%

Max Drawdown (5Y)

Largest decline over 5 years

-99.95%

-98.95%

-1.00%

Current Drawdown

Current decline from peak

-99.97%

-99.42%

-0.55%

Average Drawdown

Average peak-to-trough decline

-62.79%

-90.05%

+27.26%

Ulcer Index

Depth and duration of drawdowns from previous peaks

69.58%

24.24%

+45.34%

Volatility

LAZR vs. BOLT - Volatility Comparison

The current volatility for Luminar Technologies, Inc. (LAZR) is 0.00%, while Bolt Biotherapeutics, Inc. (BOLT) has a volatility of 21.79%. This indicates that LAZR experiences smaller price fluctuations and is considered to be less risky than BOLT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


LAZRBOLTDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

21.79%

-21.79%

Volatility (6M)

Calculated over the trailing 6-month period

192.17%

55.33%

+136.84%

Volatility (1Y)

Calculated over the trailing 1-year period

234.16%

72.84%

+161.32%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

131.58%

74.10%

+57.48%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

115.83%

75.41%

+40.42%

Dividends

LAZR vs. BOLT - Dividend Comparison

Neither LAZR nor BOLT has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

LAZR vs. BOLT - Financials Comparison

This section allows you to compare key financial metrics between Luminar Technologies, Inc. and Bolt Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M20222023202420252026
18.75M
26.00K
(LAZR) Total Revenue
(BOLT) Total Revenue
Values in USD except per share items

Frequently Asked Questions


LAZR and BOLT have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BOLT has higher volatility (21.79%) compared to LAZR (0.00%). In terms of maximum drawdown, LAZR dropped -99.97% vs BOLT's -99.51%.

BOLT currently has the higher Sharpe Ratio (-0.33 vs -0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for LAZR and BOLT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer